Search

Displaying results 4311 - 4320 of 4358 in total
  1. Drug

    Tiapride

    go.drugbank.com/drugs/DB13025
    Investigational

    Tiapride is a selective D2 and D3 dopamine receptor blocker in the brain.

  2. Drug

    Coronavirus-Like Particle COVID-19 Vaccine

    go.drugbank.com/drugs/DB15852
    Experimental

    In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known as [ISS-1018]), meant to provide an enhanced immune response to the vaccine.

  3. Drug

    Cethromycin

    go.drugbank.com/drugs/DB06419
    Investigational

    [L13988] It has also been investigated, by itself or together with [zoliflodacin], for the treatment of gonorrhea,[A203432, A203495] and was recently suggested as a possible treatment for liver-stage _

  4. Drug

    ING-1

    go.drugbank.com/drugs/DB05831
    Investigational

    ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas. It is an attractiv...

  5. Drug

    Carotuximab

    go.drugbank.com/drugs/DB06322
    Investigational

    Synonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN ENDOGLIN) (HUMAN-MUS MUSCULUS MONOCLONAL TRC105 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TRC105 .KAPPA.-CHAIN, DIMER, GAMMA1 HEAVY CHAIN (1-448) (MUS MUSCULUS VH (IGHV6-6*01-(IGHD) -IGHJ2*01) (8.10.9) (1-118) -HOMO SAPIENSIGHG1*01, GM17,1 (CH1 (119-216), HINGE (217-231), CH2(232-341), CH3 (342-446), CHS (447-448)) (119
  6. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with t...

  7. Drug

    Oral Polio Vaccine

    go.drugbank.com/drugs/DB15864
    Investigational

    The polio vaccine can be either administered in the inactivated form or the oral form, although both series comprises 4 doses and is also interchangeable in administration form so long all as 4 doses are

  8. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.

  9. Drug

    Filanesib

    go.drugbank.com/drugs/DB06040
    Investigational

    Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.

  10. Drug

    Tasosartan

    go.drugbank.com/drugs/DB01349
    Experimental

    Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.